Hirohito Takeuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hirohito Takeuchi has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Katsutoshi Sugimoto
Department of Gastroenterology and Hepatology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan
35 shared publications - Takao Itoi
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan
34 shared publications - Akihisa Ueno
Department of Pathology, School of Medicine, Tokai University, 143 Shimokasuya, Isehara 259-1193, Japan
20 shared publications - Hanako Tsujikawa
Department of Pathology, Keio University School of Medicine, Tokyo, Japan
20 shared publications - Hidenori Ojima
Department of Pathology, Keio University School of Medicine, Tokyo, Japan
20 shared publications - Kathryn Effendi
Department of Pathology, Keio University School of Medicine, Tokyo, Japan
20 shared publications
Latest Publications
- Open Access
- 22 May 2025
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 18 (4) , 1-8
Giant hepatic hemangioma with internal necrosis discovered due to fever of unknown origin and treated successfully with surgical resection: a case report
Hepatic hemangiomas are typically asymptomatic benign liver tumors. This report describes a case of a large hepatic hemangioma with internal bleeding and necrosis, presenting as fever of unknown origin, which was successfully treated with surgical resection. A woman in her 40s presented with persistent fever and fatigue. Imaging revealed a 13 cm mass in the posterior sector of the right hepatic lobe, with areas of high attenuation suggestive of internal bleeding. Laboratory tests revealed elevated levels of C-reactive protein, interleukin-6, and complement components (C3, C4, and CH50), along with an increased erythrocyte sedimentation rate. Symptomatic treatment with antipyretic medications failed to resolve the fever; therefore, hepatic resection was performed for diagnostic and therapeutic purposes. Post-operative recovery was uneventful, and the fever resolved completely. Pathological examination revealed cavernous hemangioma with well-defined necrotic areas. Post-operative blood tests showed normalization of the preoperatively elevated prognostic markers. Bleeding and necrosis associated with a large hemangioma appear to trigger the release of damage-associated molecular patterns, stimulating interleukin 6 production, promoting prostaglandin E2 synthesis, and ultimately leading to fever. Hepatic resection is an effective treatment for large hemangiomas in patients presenting with fever.
- 22 May 2025
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 18 (4) , 1-8
Open AccessGiant hepatic hemangioma with internal necrosis discovered due to fever of unknown origin and treated successfully with surgical resection: a case report
Hepatic hemangiomas are typically asymptomatic benign liver tumors. This report describes a case of a large hepatic hemangioma with internal bleeding and necrosis, presenting as fever of unknown origin, which was successfully treated with surgical resection. A woman in her 40s presented with persistent fever and fatigue. Imaging revealed a 13 cm mass in the posterior sector of the right hepatic lobe, with areas of high attenuation suggestive of internal bleeding. Laboratory tests revealed elevated levels of C-reactive protein, interleukin-6, and complement components (C3, C4, and CH50), along with an increased erythrocyte sedimentation rate. Symptomatic treatment with antipyretic medications failed to resolve the fever; therefore, hepatic resection was performed for diagnostic and therapeutic purposes. Post-operative recovery was uneventful, and the fever resolved completely. Pathological examination revealed cavernous hemangioma with well-defined necrotic areas. Post-operative blood tests showed normalization of the preoperatively elevated prognostic markers. Bleeding and necrosis associated with a large hemangioma appear to trigger the release of damage-associated molecular patterns, stimulating interleukin 6 production, promoting prostaglandin E2 synthesis, and ultimately leading to fever. Hepatic resection is an effective treatment for large hemangiomas in patients presenting with fever.
- Open Access
Usefulness of Spleen Index and Alkaline Phosphatase Level for Predicting Post‐Liver Biopsy Bleeding
Aims: The significance of liver biopsy is increasing with an increase in chronic liver disease and gene panel testing. Although non‐invasive methods such as elastography and biomarkers assess liver fibrosis, biopsy remains the definitive diagnostic gold standard. We evaluated the predictors of bleeding complications in liver biopsies.Methods and Results: A total of 697 patients were enrolled in this study between May 2017 and October 2022. We examined bleeding complications and procedures following liver biopsy and the liver biopsy needle size, blood test results, and spleen index to determine factors related to bleeding complications. Bleeding complications occurred in 23 patients (3.3%), including 20 cases at the liver puncture site, two instances of biliary bleeding, and one intercostal artery injury. The treatments varied and included hepatic arterial embolization (2 patients, 0.3%), blood transfusion therapy (3 patients, 0.4%), radiofrequency ablation (2 patients, 0.3%), endoscopic nasobiliary drainage (1 patient, 0.1%), and other treatments. In multivariate and ROC analyzes, a higher spleen index (Odds ratio: 1.13 [1.07–1.20], AUC: 0.74, optimal cut‐off value: 16.2, sensitivity: 0.74, specificity: 0.64) and ALP level (Odds ratio: 1.00 [1.00–1.01], AUC: 0.71, optimal cut‐off value: 94.5, sensitivity: 0.83, specificity: 0.49) were associated with an increased risk of bleeding. Other significant factors influencing bleeding included age, PT‐INR, needle size, and Child–Pugh score.Conclusions: The identified risk factors included spleen index and ALP level, particularly in relation to bleeding complications during liver biopsy. Therefore, these predictors should be considered before performing a liver biopsy.
Open AccessUsefulness of Spleen Index and Alkaline Phosphatase Level for Predicting Post‐Liver Biopsy Bleeding
Aims: The significance of liver biopsy is increasing with an increase in chronic liver disease and gene panel testing. Although non‐invasive methods such as elastography and biomarkers assess liver fibrosis, biopsy remains the definitive diagnostic gold standard. We evaluated the predictors of bleeding complications in liver biopsies.Methods and Results: A total of 697 patients were enrolled in this study between May 2017 and October 2022. We examined bleeding complications and procedures following liver biopsy and the liver biopsy needle size, blood test results, and spleen index to determine factors related to bleeding complications. Bleeding complications occurred in 23 patients (3.3%), including 20 cases at the liver puncture site, two instances of biliary bleeding, and one intercostal artery injury. The treatments varied and included hepatic arterial embolization (2 patients, 0.3%), blood transfusion therapy (3 patients, 0.4%), radiofrequency ablation (2 patients, 0.3%), endoscopic nasobiliary drainage (1 patient, 0.1%), and other treatments. In multivariate and ROC analyzes, a higher spleen index (Odds ratio: 1.13 [1.07–1.20], AUC: 0.74, optimal cut‐off value: 16.2, sensitivity: 0.74, specificity: 0.64) and ALP level (Odds ratio: 1.00 [1.00–1.01], AUC: 0.71, optimal cut‐off value: 94.5, sensitivity: 0.83, specificity: 0.49) were associated with an increased risk of bleeding. Other significant factors influencing bleeding included age, PT‐INR, needle size, and Child–Pugh score.Conclusions: The identified risk factors included spleen index and ALP level, particularly in relation to bleeding complications during liver biopsy. Therefore, these predictors should be considered before performing a liver biopsy.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Purpose:Immunotherapies have led to a paradigm shift in the treatment of hepatocellular carcinoma (HCC). Studies have revealed the single-cell catalogs of tumor-infiltrating immune cells and the trajectories of their differentiation. Nevertheless, the spatial distribution of these immune cells with distinct phenotypes in the tumor microenvironment and their clinicopathologic significance in resectable and unresectable HCCs are still largely unclear.Experimental Design:We analyzed the spatial dynamics of intratumoral CD4 and CD8 T cells and their association with B and plasma cells using 283 surgically resected HCC samples, 58 unresectable HCC samples before combined immunotherapy [atezolizumab plus bevacizumab (Atezo + Bev)], and autopsy specimens from 50 cases of advanced-stage HCC through multiplex IHC combined with transcriptomic and driver gene mutation analyses. Classification based on the spatial dynamics of T- and B-cell responses (refined immunosubtype) was developed, and its clinicopathologic significance was analyzed.Results:We found that stem-like CD4 and CD8 T cells were mainly observed in T-cell aggregates and T-cell zone of tertiary lymphoid structure (TLS). The differentiation of T follicular helper cells was associated with the development of TLS, whereas the differentiation of CXCL13-expressing CD4 TCXCL13 cells with a phenotype resembling T peripheral helper cells was associated with the development of the lymphoplasmacytic microenvironment. The refined immunosubtype could predict clinical outcomes of resectable HCC after surgery and unresectable HCC after Atezo + Bev therapy. The immune microenvironment of metastatic lesions tended to reflect those of primary lesions.Conclusions:We revealed the spatial dynamics of T- and B-cell responses in HCC, which is closely associated with the clinical outcome after surgical resection or Atezo + Bev therapy.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Purpose:Immunotherapies have led to a paradigm shift in the treatment of hepatocellular carcinoma (HCC). Studies have revealed the single-cell catalogs of tumor-infiltrating immune cells and the trajectories of their differentiation. Nevertheless, the spatial distribution of these immune cells with distinct phenotypes in the tumor microenvironment and their clinicopathologic significance in resectable and unresectable HCCs are still largely unclear.Experimental Design:We analyzed the spatial dynamics of intratumoral CD4 and CD8 T cells and their association with B and plasma cells using 283 surgically resected HCC samples, 58 unresectable HCC samples before combined immunotherapy [atezolizumab plus bevacizumab (Atezo + Bev)], and autopsy specimens from 50 cases of advanced-stage HCC through multiplex IHC combined with transcriptomic and driver gene mutation analyses. Classification based on the spatial dynamics of T- and B-cell responses (refined immunosubtype) was developed, and its clinicopathologic significance was analyzed.Results:We found that stem-like CD4 and CD8 T cells were mainly observed in T-cell aggregates and T-cell zone of tertiary lymphoid structure (TLS). The differentiation of T follicular helper cells was associated with the development of TLS, whereas the differentiation of CXCL13-expressing CD4 TCXCL13 cells with a phenotype resembling T peripheral helper cells was associated with the development of the lymphoplasmacytic microenvironment. The refined immunosubtype could predict clinical outcomes of resectable HCC after surgery and unresectable HCC after Atezo + Bev therapy. The immune microenvironment of metastatic lesions tended to reflect those of primary lesions.Conclusions:We revealed the spatial dynamics of T- and B-cell responses in HCC, which is closely associated with the clinical outcome after surgical resection or Atezo + Bev therapy.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S4. Clinicopathological findings in cases treated with Atezo+Bev therapy
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S4. Clinicopathological findings in cases treated with Atezo+Bev therapy
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S2. Example of histocytometric analysis
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S2. Example of histocytometric analysis
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S5. Intratumoral distribution of NK cells
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S5. Intratumoral distribution of NK cells
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S3. Multivariate analysis for DFS in Cohort 1 + 2 (n = 268)
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S3. Multivariate analysis for DFS in Cohort 1 + 2 (n = 268)
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S7. CD68+ and CD169+ macrophages in TA/TLS
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S7. CD68+ and CD169+ macrophages in TA/TLS
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S6. Clinicopathological findings in autopsy cases.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Table S6. Clinicopathological findings in autopsy cases.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S4. TCF1 expression in TA and TLS
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Spatial Dynamics of T- and B-Cell Responses Predicts Clinical Outcome of Resectable and Unresectable Hepatocellular Carcinoma
Figure S4. TCF1 expression in TA and TLS